- Home
- AVIR vs CGC Comparison
AVIR vs CGC Comparison
Compare AVIR & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | CGC |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 389.2M |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AVIR | CGC |
|---|---|---|
| Price | $5.21 | $0.94 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 239.9K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.00 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $351,367,000.00 | $12,759,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $15.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $0.84 |
| 52 Week High | $6.45 | $2.38 |
Technical Indicators
Market Signals| Indicator | AVIR | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 47.16 | 45.92 |
| Support Level | $5.09 | $0.91 |
| Resistance Level | $5.79 | $1.15 |
| Average True Range (ATR) | 0.23 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 23.53 | 30.00 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
About CGC Canopy Growth Corporation
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.